Nanomedicine Market Report by Nanomolecule Type, Product, Application, and Region 2024-2032
세계 나노의학 시장 규모는 2023년 2,639억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 7,195억 달러에 이르며, 2024년과 2032년 사이에 11.4%의 성장률(CAGR)을 나타낼 것으로 예측했습니다.
나노의학은 분자 수준에서 질병을 치료하고 조직을 복구하는 데 사용되는 프로그래밍 가능한 특성을 가진 특수 다기능 약물을 의미합니다. 여기에는 진단, 치료, 장애 예방, 기본 병태생리학 분석을 위해 이미징제, 나노로봇, 바이오칩, 고분자 치료제와 같은 나노입자, 나노튜브, 나노디바이스를 사용하는 것이 포함됩니다. 나노입자는 금속 및 금속 산화물, 리포솜, 무기 입자 등을 포함하며, 이들은 약물의 수송 및 신체의 도달하기 어려운 부위를 표적으로 하는데 사용됩니다. 그 결과 나노의학은 약물 전달, 영상 진단, 백신, 재생 의료, 임플란트 등에 광범위하게 응용되고 있습니다.
나노의학 시장 경향 :
세계에서 만성 질환의 유병률이 증가하고 있는 것이 시장 전망을 밝게 하는 주요 요인 중 하나입니다. 나노의료는 종양학, 신경학, 비뇨기학, 감염, 안과, 정형외과, 면역학, 심혈관 질환의 치료에 매우 유용합니다. 이에 따라 개인화된 의약품에 대한 선호도 변화도 시장 성장에 기여합니다. 또한, 진단 절차를 개선하기 위한 나노 스케일 기술의 다양한 기술 진보가 다른 성장 촉진요인으로 작용하고 있습니다. 제약 제조업체는 나노 로봇 시스템 및 기타 새로운 솔루션을 사용하여 나노 의약품을 효과적으로 투여하고 있습니다. 헬스케어 인프라 개선, 생명공학 분야에서 광범위한 R&D 활동 등 다른 요인들도 시장 성장을 가속할 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 나노의학 시장 세계 시장 규모는?
- 2024년부터 2032년까지 세계의 나노의학 시장의 예상 성장률은?
- 세계의 나노의학 시장을 견인하는 주요 요인은?
- 세계의 나노의학 시장에 대한 COVID-19의 영향은?
- 나노 분자 유형을 기반으로 세계의 나노의학 시장 내역은?
- 세계의 나노의학 시장의 제품별 내역은?
- 세계의 나노의학 시장의 용도별 내역은?
- 세계 나노의학 시장의 주요 지역은?
- 세계의 나노의학 시장에서 주요 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 나노의학 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 나노분자 유형별
- 나노입자
- 시장 동향
- 주요 유형
- 금속 및 금속 산화물 나노입자
- 리포솜
- 폴리머 및 폴리머 약물 복합체
- 히드로겔 나노입자
- 덴드리머
- 무기 나노입자
- 시장 예측
- 나노쉘
- 나노튜브
- 나노 디바이스
제7장 시장 분석 : 제품별
제8장 시장 분석 : 용도별
- 임상 종양학
- 감염증
- 임상 심장 병학
- 정형외과
- 기타
제9장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- Arrowhead Pharmaceuticals Inc.
- General Electric Company
- Luminex Corporation
- Merck & Co. Inc.
- Nanobiotix
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Starpharma Holdings Limited
JHS
The global nanomedicine market size reached US$ 263.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 719.5 Billion by 2032, exhibiting a growth rate (CAGR) of 11.4% during 2024-2032.
Nanomedicine refers to specialized multi-functional drugs with programmable properties used for the treatment of diseases and repairing tissues at a molecular level. It involves the use of nanoparticles, nanotubes and nanodevices, such as imaging agents, nanorobots, biochips and polymer therapeutics, for the diagnosis, treatment and prevention of a disorder and analyzing the underlying pathophysiology. The nanoparticles include metal and metal oxides, liposomes and inorganic particles, which are used for transporting the drugs and targeting difficult to reach areas in the body. As a result, nanomedicine finds extensive applications for drug delivery, diagnostic imaging, vaccines, regenerative medicines and implants.
Nanomedicine Market Trends:
The increasing prevalence of chronic medical ailments across the globe is one of the key factors creating a positive outlook for the market. Nanomedicine is highly beneficial in the treatment of oncological, neurological, urological, infectious, ophthalmological, orthopedic, immunological and cardiovascular diseases. In line with this, shifting preference for personalized medicines is also contributing to the growth of the market. Additionally, various technological advancements in the nanoscale technologies for improved diagnostic procedures are acting as other growth-inducing factors. Pharmaceutical manufacturers are using nanorobotic systems and other novel solutions for the effective administration of nanomedicines. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biotechnology, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global nanomedicine market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on nanomolecule type, product and application.
Breakup by Nanomolecule Type:
Nanoparticles
Metal and Metal Oxide Nanoparticles
Liposomes
Polymers and Polymer Drug Conjugates
Hydrogel Nanoparticles
Dendrimers
Inorganic Nanoparticles
Nanoshells
Nanotubes
Nanodevices
Breakup by Product:
Therapeutics
Regenerative Medicine
In-Vitro Diagnostics
In-Vivo Diagnostics
Vaccines
Breakup by Application:
Clinical Oncology
Infectious Diseases
Clinical Cardiology
Orthopedics
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arrowhead Pharmaceuticals Inc., General Electric Company, Luminex Corporation, Merck & Co. Inc., Nanobiotix, Novartis AG, Pfizer Inc., Sanofi SA and Starpharma Holdings Limited.
Key Questions Answered in This Report
- 1. How big is the global nanomedicine market?
- 2. What is the expected growth rate of the global nanomedicine market during 2024-2032?
- 3. What are the key factors driving the global nanomedicine market?
- 4. What has been the impact of COVID-19 on the global nanomedicine market?
- 5. What is the breakup of the global nanomedicine market based on the nanomolecule type?
- 6. What is the breakup of the global nanomedicine market based on the product?
- 7. What is the breakup of the global nanomedicine market based on the application?
- 8. What are the key regions in the global nanomedicine market?
- 9. Who are the key players/companies in the global nanomedicine market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Nanomedicine Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Nanomolecule Type
- 6.1 Nanoparticles
- 6.1.1 Market Trends
- 6.1.2 Major Types
- 6.1.2.1 Metal and Metal Oxide Nanoparticles
- 6.1.2.2 Liposomes
- 6.1.2.3 Polymers and Polymer Drug Conjugates
- 6.1.2.4 Hydrogel Nanoparticles
- 6.1.2.5 Dendrimers
- 6.1.2.6 Inorganic Nanoparticles
- 6.1.3 Market Forecast
- 6.2 Nanoshells
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Nanotubes
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Nanodevices
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Product
- 7.1 Therapeutics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Regenerative Medicine
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 In-Vitro Diagnostics
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 In-Vivo Diagnostics
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Vaccines
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Application
- 8.1 Clinical Oncology
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Infectious Diseases
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Clinical Cardiology
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Orthopedics
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Arrowhead Pharmaceuticals Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 General Electric Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.4 Luminex Corporation
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Merck & Co. Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Nanobiotix
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Novartis AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi SA
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Starpharma Holdings Limited
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
